Meeting
2024 ASCO Breakthrough
Potential for boron neutron capture therapy (BNCT) with ASCT2-targeted boron agents.
Authors
Kenichiro Eza
Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatuki, Japan
Kenichiro Eza , Kohei Tsujino , Shinji Kawabata , Yoshiki Fujikawa , Hideki Kashiwagi , Gen Hutamura , Ryo Hiramastu , Sinichi Miyatake , Hiroki Tanaka , Minoru Suzuki , Masahiko Wanibuchi , Hiroyuki Nakamura , Tomoyuki Araki , Taiki Morita
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Targeted Therapies
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 233)
DOI
10.1200/JCO.2024.42.23_suppl.233
Abstract #
233
Poster Bd #
H10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
The efficacy of boron neutron capture therapy with folate receptor targeted novel boron carrier in F98 rat brain tumor models.
First Author: Kohei Tsujino
Poster
2020 ASCO Virtual Scientific Program
Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.
First Author: Abed Rahman Kawakibi
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Yoga program for patients with brain tumors undergoing radiotherapy (XRT) and their family caregivers.
First Author: Kathrin Milbury
Poster
2014 ASCO Annual Meeting
Oncolytic viral therapy for malignant gliomas using myxoma virus deleted for antiapoptotic M11L gene.
First Author: Peter A. J. Forsyth